Exploration of Immune Targets for Type 1 Diabetes and Latent Autoimmune Disease Immunotherapy
Khalid Siddiqui,* Shaik Sarfaraz Nawaz* Strategic Center for Diabetes Research, College of Medicine, King Saud University, Riyadh, Saudi Arabia*These authors contributed equally to this workCorrespondence: Khalid Siddiqui, Strategic Center for Diabetes Research, College of Me...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-09-01
|
| Series: | ImmunoTargets and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/exploration-of-immune-targets-for-type-1-diabetes-and-latent-autoimmun-peer-reviewed-fulltext-article-ITT |
| _version_ | 1797669421220626432 |
|---|---|
| author | Siddiqui K Nawaz SS |
| author_facet | Siddiqui K Nawaz SS |
| author_sort | Siddiqui K |
| collection | DOAJ |
| description | Khalid Siddiqui,* Shaik Sarfaraz Nawaz* Strategic Center for Diabetes Research, College of Medicine, King Saud University, Riyadh, Saudi Arabia*These authors contributed equally to this workCorrespondence: Khalid Siddiqui, Strategic Center for Diabetes Research, College of Medicine, King Saud University, P.O. Box 245, Riyadh, 11411, Saudi Arabia, Tel +966 114724179 Ext.3106 ; +966 530202763, Email ksiddiqui@ksu.edu.saAbstract: Type 1 diabetes (T1D) is an autoimmune disease that destroys pancreatic beta cells, which produce insulin in the islets of Langerhans. The risk of developing T1D is influenced by environmental factors, genetics, and autoantibodies. Latent autoimmune diabetes in adults (LADA) is a type of T1D that is genetically and phenotypically distinct from classic T1D. This review summarizes the accumulated information on the risk factors for T1D and LADA, and immunotherapy trials that offer insights into potential future combined therapeutic interventions for both T1D and LADA to slow the rate of islet cell loss and preserve beta cell function. Future research should also focus on improving intervention doses, conducting more thorough examinations of intervention responders, and/or combining minimally effective single-target immunotherapies to slow the rate of islet cell loss and preserve beta cell function.Keywords: type 1 diabetes, LADA, immunotherapy, islet cells |
| first_indexed | 2024-03-11T20:44:07Z |
| format | Article |
| id | doaj.art-1b3a1ea64912497db8f5141717cd31e8 |
| institution | Directory Open Access Journal |
| issn | 2253-1556 |
| language | English |
| last_indexed | 2024-03-11T20:44:07Z |
| publishDate | 2023-09-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | ImmunoTargets and Therapy |
| spelling | doaj.art-1b3a1ea64912497db8f5141717cd31e82023-10-01T18:14:19ZengDove Medical PressImmunoTargets and Therapy2253-15562023-09-01Volume 129110387057Exploration of Immune Targets for Type 1 Diabetes and Latent Autoimmune Disease ImmunotherapySiddiqui KNawaz SSKhalid Siddiqui,* Shaik Sarfaraz Nawaz* Strategic Center for Diabetes Research, College of Medicine, King Saud University, Riyadh, Saudi Arabia*These authors contributed equally to this workCorrespondence: Khalid Siddiqui, Strategic Center for Diabetes Research, College of Medicine, King Saud University, P.O. Box 245, Riyadh, 11411, Saudi Arabia, Tel +966 114724179 Ext.3106 ; +966 530202763, Email ksiddiqui@ksu.edu.saAbstract: Type 1 diabetes (T1D) is an autoimmune disease that destroys pancreatic beta cells, which produce insulin in the islets of Langerhans. The risk of developing T1D is influenced by environmental factors, genetics, and autoantibodies. Latent autoimmune diabetes in adults (LADA) is a type of T1D that is genetically and phenotypically distinct from classic T1D. This review summarizes the accumulated information on the risk factors for T1D and LADA, and immunotherapy trials that offer insights into potential future combined therapeutic interventions for both T1D and LADA to slow the rate of islet cell loss and preserve beta cell function. Future research should also focus on improving intervention doses, conducting more thorough examinations of intervention responders, and/or combining minimally effective single-target immunotherapies to slow the rate of islet cell loss and preserve beta cell function.Keywords: type 1 diabetes, LADA, immunotherapy, islet cellshttps://www.dovepress.com/exploration-of-immune-targets-for-type-1-diabetes-and-latent-autoimmun-peer-reviewed-fulltext-article-ITTtype 1 diabetesladaimmunotherapyislet cells |
| spellingShingle | Siddiqui K Nawaz SS Exploration of Immune Targets for Type 1 Diabetes and Latent Autoimmune Disease Immunotherapy ImmunoTargets and Therapy type 1 diabetes lada immunotherapy islet cells |
| title | Exploration of Immune Targets for Type 1 Diabetes and Latent Autoimmune Disease Immunotherapy |
| title_full | Exploration of Immune Targets for Type 1 Diabetes and Latent Autoimmune Disease Immunotherapy |
| title_fullStr | Exploration of Immune Targets for Type 1 Diabetes and Latent Autoimmune Disease Immunotherapy |
| title_full_unstemmed | Exploration of Immune Targets for Type 1 Diabetes and Latent Autoimmune Disease Immunotherapy |
| title_short | Exploration of Immune Targets for Type 1 Diabetes and Latent Autoimmune Disease Immunotherapy |
| title_sort | exploration of immune targets for type 1 diabetes and latent autoimmune disease immunotherapy |
| topic | type 1 diabetes lada immunotherapy islet cells |
| url | https://www.dovepress.com/exploration-of-immune-targets-for-type-1-diabetes-and-latent-autoimmun-peer-reviewed-fulltext-article-ITT |
| work_keys_str_mv | AT siddiquik explorationofimmunetargetsfortype1diabetesandlatentautoimmunediseaseimmunotherapy AT nawazss explorationofimmunetargetsfortype1diabetesandlatentautoimmunediseaseimmunotherapy |